Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

NTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study wi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- CytRx Corporation (NASDAQ: CYTR ), a ... that data regarding the Company,s Phase 2b global clinical ... tissue sarcoma (STS) will be presented in a moderated ... (CTOS) Annual Meeting which is being held October 15-18, ... the longer than expected survival of patients in the ...
(Date:10/16/2014)...  One of California,s most ... the Patient Advocate — this week recognized Kaiser Permanente,s ... state for the seventh consecutive year. The ... and Kaiser Permanente Southern California are the only health ... a four-star rating — the highest possible — for ...
(Date:10/16/2014)... YORK , Oct. 16, 2014 Curtis ... organizer is under 3 weeks away from hosting their co-located ... and Oral Drug Formulation Innovations Summit taking ... San Diego, CA. November,s ... development organizations in streamlining the bioequivalence testing process, as ...
Breaking Medicine Technology:CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 2Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 3Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2
... July 14 ERT (Nasdaq: ERES ) announced today that ... August 9, 2010 , after the market closes. After the release, the Company ... , , , ... participants should dial 1-800-860-2442 when calling within the United States or ...
... , HONOLULU , July 14 EnVivo ... on Alzheimer,s Disease (ICAD) results from its proprietary gamma-secretase modulator ... reduced amyloid plaque buildup which is believed to be a ... inflammation associated with Alzheimer,s disease. , ...
Cached Medicine Technology:ERT to Announce Second Quarter 2010 Results on August 9, 2010 2EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease 2
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... SUNDAY, Oct. 19, 2014 (HealthDay News) -- New stem ... eventually lead to new treatments, a new study suggests. ... functioning human intestinal tissue in a lab dish. They ... model for studying intestinal disorders, according to the researchers. ... many diseases and conditions that can cause intestinal failure, ...
(Date:10/19/2014)... Nearly 9,000 transvaginal mesh lawsuits ( ... Johnson’s Ethicon unit have now been centralized in New ... are continuing to move forward, Bernstein Liebhard LLP reports. ... over products part of Ethicon Inc.’s line of Gynecare ... 11th, 2014, which showed an additional 1,600 claims now ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4
... 16 (HealthDay News) -- Women with rheumatoid arthritis or ... hoped for, according to a new study. These ... cause fertility problems and miscarriage, researchers said. Lupus ... and organs. Rheumatoid arthritis leads to painful joint inflammation. ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... of blood clots in people undergoing certain cancer treatments, ... treated with chemotherapy, they have an increased risk of ... dangerous, and have the potential to cause heart attacks ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Feb. ... also help problem drinkers cut their alcohol consumption, a ... drug curbs drinking is not fully understood, but its ... of sadness and nausea, thereby blunting the pleasurable effects ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... require driver,s education before getting a license, about one-third ... half fail to undergo any formal behind-the-wheel training. ... records were especially unlikely to have received driver,s ed ...
... 15, 2012 California reported the largest decline in drunk-driving ... to recent statistics, and a $232,000 grant from the California ... Safety Administration to UC Irvine,s Health Education Center is ... with the RADD College DUI Awareness Program, UCI has organized ...
... -- Takemi Tanaka, Ph.D., of Thomas Jefferson University,s School ... , received a $50,000 grant toward her breast cancer research, ... for Breast and Cervical Cancer Research" initiative. The ... who choose to contribute all or part of their state ...
Cached Medicine News:Health News:Lupus, Rheumatoid Arthritis Linked to Fertility Woes, Miscarriage 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 3Health News:Stop-Smoking Drug May Also Curb Problem Drinking 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 3Health News:UCI leads multicampus collaboration to reward use of designated drivers 2Health News:Taxpayers give back for cancer: Jefferson researcher awarded 'Refunds for Research' grant 2
... fixation. Completely resorbable, it presented surgeons with ... the most thoroughly proven product of its ... with system enhancements that make it even ... system means that application of this proven ...
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... ultrasound A-scan Sonomed-315 is intended for visualization ... detection of midline shifts in the brain, ... and easy to use, the Sonomed-315 offers ... A-scanning mode allows to identify the anatomic ...
... With Plasmaseal's Proteus device the two steps ... is injected into Proteus' single use disposable ... base unit. The operator touches a button, ... is separated by centrifugation. Then the integral ...
Medicine Products: